Iovance Biotherapeutics (IOVA) projects 2026 revenue of $350M–$370M and cash runway into 2028
Iovance Biotherapeutics has updated its corporate outlook, projecting Q2 2026 revenue of $86M–$88M and full-year 2026 revenue of $350M–$370M, with a cash runway extending into 2028. The company highlights the commercial progress of Amtagvi, its FDA-approved T cell therapy for advanced melanoma, and advancements in its pipeline for other solid tumors. Key figures include over 90 authorized treatment centers, coverage for more than 200 million patient lives, and promising clinical data for Amtagvi and next-generation TIL therapies.
IOVA - Why I think Iovance is undervalued
The author believes Iovance Biotherapeutics (IOVA) is undervalued, with the market focusing on past setbacks rather than future potential. They highlight the approval of Amtagvi, a TIL therapy, and improving commercial performance, expecting strong revenue growth in 2026. The article also discusses the long-term potential of the TIL platform for other cancers and the possibility of Iovance becoming an attractive acquisition target for larger pharmaceutical companies.
Did You Lose Money on Iovance Biotherapeutics, Inc. (IOVA)? Levi
Levi & Korsinsky LLP has filed a class action securities lawsuit against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) for alleged securities fraud between May 9, 2024, and May 8, 2025. The lawsuit claims that Iovance made misleading statements about its growth potential, failing to disclose its inability to meet demand for its treatments, which led to a significant stock price drop on May 9, 2025. Investors who suffered losses are urged to contact the firm before July 14, 2025, to learn about their rights to recovery.
Iovance Biotherapeutics updates corporate presentation, reiterates $350M–$370M FY26 guidance
Iovance Biotherapeutics has updated its corporate presentation, reaffirming its revenue guidance for FY2026 at $350M–$370M and Q2 2026 guidance at $86M–$88M. The company reported a cash balance of $319M as of March 31, 2026, with a runway extending into 2028. Key highlights include its commercial footprint with over 90 Authorized Treatment Centers and pipeline plans for frontline melanoma and NSCLC programs.
IOVA - Iovance Biotherapeutics Inc Options
This article provides a detailed financial overview of Iovance Biotherapeutics Inc. (IOVA), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights the company's valuation, profitability, growth rates, and various trading indicators, along with a promotion for Finviz Elite.
Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript
This article provides the transcript from the Iovance Biotherapeutics Inc Annual Shareholders Meeting held on June 10, 2026. The meeting was conducted virtually, with Chairman Ian Dukes presiding and key officers like Colleen Roche (CFO) and Fred Boit (Interim CEO, President, and General Counsel) in attendance. The transcript details the formal opening of the meeting by the Chairman.
Enterprise value to revenue forward of Iovance Biotherapeutics Inc – SWB:2LB
This article provides financial information for Iovance Biotherapeutics Inc. It displays the enterprise value to revenue forward for the company, accessible through its listing on the Stuttgart Stock Exchange under the ticker 2LB. The content is primarily a data page from TradingView, focusing on market financials.
Enterprise value to EBIT forward of Iovance Biotherapeutics Inc – SWB:2LB
The article provides a single financial metric for Iovance Biotherapeutics Inc (SWB:2LB) on the Stuttgart Stock Exchange: its enterprise value to EBIT forward. It indicates that the market was closed with no trades recorded at the time of publication. The content primarily focuses on presenting this specific financial data point within the context of the company's profile on TradingView.
Price to sales forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA
This article provides financial information for Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), specifically focusing on its forward price-to-sales ratio. It briefly mentions real-time market data providers and copyright information related to financial data. The content is presented in a data-centric format from TradingView.
Price to sales forward of Iovance Biotherapeutics Inc – LS:A2DT49
This article provides financial data for Iovance Biotherapeutics Inc (LS:A2DT49), specifically focusing on its forward price-to-sales ratio. It appears to be a section from a financial data platform, likely TradingView, showing stock information and navigational links related to the company's financials.
Iovance Biotherapeutics Inc Actuals & Estimates (NASDAQ:IOVA)
This article provides an overview of Iovance Biotherapeutics Inc. (NASDAQ:IOVA) including its current stock price, historical performance, analyst forecasts, and financial data. It covers key metrics such as market capitalization, an upcoming earnings report, and past earnings and revenue figures.
Price to earnings forward of Iovance Biotherapeutics Inc – LS:A2DT49
This page provides financial data specifically on the "Price to earnings forward" metric for Iovance Biotherapeutics Inc (LS:A2DT49) from TradingView. The article indicates the market is closed for this stock and presents the data under its financial overview section.
Iovance Biotherapeutics (IOVA) Wins Australia Approval For Amtagvi In Melanoma
Iovance Biotherapeutics (IOVA) has received conditional approval in Australia for Amtagvi, its T-cell therapy for advanced melanoma, marking its third market authorization after the US and Canada. This approval expands the company's geographic reach and potential revenue streams, reinforcing the viability of its cell therapy platform for solid tumors. Investors will now monitor the rollout, including the activation of treatment centers and clinician uptake in Australia, to assess the financial impact of this expansion.
Iovance (IOVA) Surges 9.4% on Regulatory Nod
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) saw its shares surge by 9.4% following regulatory approval from Australia's Therapeutic Goods Administration (TGA) for its tumor-derived immunotherapy, Amtagvi. This approval is the third marketing authorization globally for Amtagvi, enabling Iovance to expand into a market with a high rate of melanoma. The company plans to establish its first Australian treatment center as part of its expansion strategy.
Iovance (IOVA) Surges 9.4% on Regulatory Nod
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) saw its shares rise by 9.36% after securing conditional approval from Australia's Therapeutic Goods Administration (TGA) for Amtagvi, its tumor-derived T-cell immunotherapy. This approval allows Iovance to expand into the Australian market, which has the world's highest melanoma rate, and marks the company's third marketing authorization for Amtagvi. The TGA's decision was based on positive safety and efficacy data from the C-144-01 trial.
IOVA Stock Climbs As Amtagvi Wins Australia Nod And Pipeline Expands
Iovance Biotherapeutics Inc. (IOVA) stock climbed by 8.5% following the conditional approval of its cancer therapy, Amtagvi, in Australia for advanced melanoma. This marks its third global marketing authorization and first T-cell therapy for solid tumors in that market. Additionally, the FDA cleared an IND for IOV-5001, expanding Iovance’s TIL platform and pipeline of potential catalysts, along with the company filing an automatic mixed securities shelf to fund its operations.
Iovance Biotherapeutics Inc (IOVA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Iovance Biotherapeutics Inc (IOVA), noting its current price momentum score of 6.95 and its trading range between a resistance level of $4.53 and a support level of $3.64. It details various technical indicators like MACD, RSI, and moving averages, concluding with a "Buy" signal based on the overall analysis. The article also includes FAQs explaining technical ratings and moving averages.
Iovance Biotherapeutics (IOVA) Stock Could Be 53.2% Undervalued After New Shelf Filings
Iovance Biotherapeutics (IOVA) recently filed new shelf registrations, providing flexibility for future capital raising and employee incentives. Despite some short-term share price softening, the company has seen strong longer-term momentum with significant year-to-date and 1-year returns. Its stock is currently trading at a large discount to the average analyst price target, indicating it could be significantly undervalued, with a fair value estimated at $8.35 per share.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. announced the grant of inducement stock options covering 140,860 shares of its common stock to twenty-seven new, non-executive employees on June 18, 2026. These awards were made under Iovance's Amended and Restated 2021 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $3.91, vesting over a three-year period. The company specializes in developing tumor infiltrating lymphocyte (TIL) therapies for cancer patients.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics announced the grant of inducement stock options for 140,860 shares of its common stock to twenty-seven new, non-executive employees. The options were granted on June 18, 2026, with an exercise price of $3.91, in accordance with Nasdaq Listing Rule 5635(c)(4). These awards will vest over a three-year period, tied to continued employment.
Iovance Biotherapeutics grants stock options to 27 new employees under Nasdaq rules.
Iovance Biotherapeutics has approved inducement stock options for 140,860 shares to 27 new non-executive employees, with an exercise price of $3.91 and a three-year vesting period. This move complies with Nasdaq Listing Rule 5635(c)(4) and is intended to promote employee retention and support the company's efforts in cancer therapy innovation. Iovance continues its focus on advancing tumor-infiltrating lymphocyte therapies, including the FDA-approved Amtagvi®.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics announced the grant of inducement stock options for 140,860 shares to twenty-seven new non-executive employees on June 18, 2026. These options were granted under the company's Amended and Restated 2021 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $3.91 and vest over a three-year period, contingent on continued employment.
Iovance Biotherapeutics Grants Inducement Stock Options to 27 New Employees
Iovance Biotherapeutics has granted inducement stock options covering 140,860 shares to 27 new non-executive employees, with an exercise price of $3.91, the closing price on June 18, 2026. These options vest over three years and are part of the company's Amended and Restated 2021 Inducement Plan, aligning with Nasdaq regulations. The move aims to motivate employees and supports Iovance's focus on advancing tumor-infiltrating lymphocyte therapies for cancer treatment.
Iovance Biotherapeutics Inc (IOVA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Iovance Biotherapeutics Inc (IOVA) has an earnings forecast score of 7.64, ranking 280 out of 388 in its industry. Analysts have an average price target of $9.00 for IOVA, with a "Buy" rating from 10 analysts. The company's expected revenue for the next quarter is $87.76M, and its expected EPS is -$0.13.
Iovance Biotherapeutics Inc Files For Mixed Shelf
Iovance Biotherapeutics Inc. has filed for a mixed shelf offering, according to a report from Refinitiv. This type of filing allows a company to offer a variety of securities over a period of time without having to register each offering separately. The news was published on TradingView News.
Iovance Biotherapeutics (IOVA) grants 90,316 deferred stock units to director
Iovance Biotherapeutics (IOVA) director Ryan D. Maynard was granted 90,316 deferred restricted stock units (DRSUs) as compensation under the company's 2018 Equity Incentive Plan. These units, each representing one share of common stock, will vest upon R. Maynard's continued service for either one year from the grant date or until the day before the next annual shareholder meeting. The actual settlement in common stock is deferred until specified events occur, such as his departure from the board or a change in control, with a maximum deferral period of ten years.
IOVANCE BIOTHERAPEUTICS (IOVA) director receives 90,316 deferred stock units
IOVANCE BIOTHERAPEUTICS director Athena Countouriotis has been granted 90,316 deferred restricted stock units (DRSUs) as part of the company’s 2018 Equity Incentive Plan. These DRSUs, which represent contingent rights to receive common stock, will vest based on her continued service and are deferred until specific events such as the end of her board service or a change in control. This transaction is a compensation-related grant, not an open-market trade, and the units were awarded at no cash cost.
IOVANCE (IOVA) awards 15,000 restricted stock units to Chief Regulatory Officer Raj K. Puri
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has granted Chief Regulatory Officer Raj K. Puri 15,000 restricted stock units (RSUs) as compensation. These RSUs will vest over three years, with one-third after the first year and the remainder in quarterly installments over the subsequent two years, contingent on continued employment. This award aims to incentivize retention and align the officer's interests with the company's long-term performance.
Iovance Biotherapeutics Inc (IOVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Iovance Biotherapeutics Inc (IOVA), detailing its regional revenue contributions. As of the specified update date, comprehensive data for business segments and future fiscal quarters (FY2025Q1-Q4) has not been disclosed by the company. The currently available regional data indicates that the United States accounts for the vast majority of the company's reported revenue.
Iovance Biotherapeutics: Commercial, Clinical, And Regulatory Tailwinds (NASDAQ:IOVA)
Iovance Biotherapeutics (IOVA) projects strong revenue growth for 2026, driven by its drug Amtagvi and planned expansion into new indications like NSCLC, endometrial, and sarcoma. The company anticipates accelerated approvals due to a more receptive FDA stance on single-arm data, streamlining its development path. With current cash reserves expected to last into early 2028, Iovance is positioned for growth, potentially supported by further fundraising via its at-the-market facility.
H.C. Wainwright Remains a Buy on Iovance Biotherapeutics (IOVA)
H.C. Wainwright reiterated a Buy rating on Iovance Biotherapeutics (IOVA) with a $9 price target, citing two positive developments for its lead therapy, AMTAGVI. These include conditional approval in Australia, offering a new revenue stream, and strong long-term data presented at ASCO 2026, reinforcing the therapy's durability in melanoma patients. Despite acknowledging inherent risks, the analyst sees a compelling risk-reward with international expansion and supportive clinical data.
What Iovance Biotherapeutics (IOVA)'s Australia Amtagvi Nod and New TIL Trial Mean for Shareholders
Iovance Biotherapeutics (IOVA) recently received conditional approval for Amtagvi in Australia and FDA clearance for Phase 1/2 trials of its new TIL therapy, IOV-5001. These developments, along with shareholder approval to increase authorized stock, highlight the company's efforts to expand its TIL platform and geographic reach. The article explores how these events could impact Iovance's investment outlook and long-term growth, while also noting the company's reliance on Amtagvi and its complex manufacturing model, as well as ambitious revenue and earnings projections.
Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript
This article provides the transcript from Iovance Biotherapeutics Inc.'s Annual Shareholders Meeting held on June 10, 2026. The meeting was conducted virtually and included remarks from the Chairman of the Board, Ian Dukes, and attendance by CFO Colleen Roche and Interim CEO Fred Boit. The article contextually lists various past and future earnings calls and conference transcripts for Iovance Biotherapeutics (NAS:IOVA).
Iovance (NASDAQ: IOVA) gains Australian Amtagvi approval as shareholders back larger share pool
Iovance Biotherapeutics (NASDAQ: IOVA) has received marketing authorization from Australia's Therapeutic Goods Administration (TGA) for its advanced melanoma drug, Amtagvi (lifileucel). This approval marks Amtagvi as the first T cell therapy for solid tumor cancer and the first post-anti-PD-1 option for advanced melanoma in Australia, a country with a high incidence of the disease. Concurrently, Iovance shareholders approved all proposals at their Annual Meeting, including an increase in authorized common stock and an expansion of the Employee Stock Purchase Plan, providing the company with greater financial and equity flexibility.
Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001
Iovance Biotherapeutics (IOVA) has seen significant advancements in its TIL therapy platform, evidenced by Australia's approval of Amtagvi for advanced melanoma and the FDA's clearance for its investigational new drug application for IOV-5001. IOV-5001, a next-generation IL-12-tethered TIL therapy, is designed to target various solid tumors, with a Phase 1/2 trial planned for the second half of 2026. Despite a 54.95% year-to-date gain, analysts see further upside potential for the company.
Iovance Biotherapeutics (IOVA) Advances Next-Generation TIL Pipeline With FDA Clearance for IOV-5001
Iovance Biotherapeutics (IOVA) has seen significant advancements in its TIL therapy platform with two key developments. The company received conditional approval from Australia's TGA for Amtagvi (lifileucel) to treat advanced melanoma, and the FDA granted allowance for an investigational new drug application for IOV-5001, a next-generation IL-12-tethered TIL therapy. A Phase 1/2 basket trial for IOV-5001 is set to begin in the second half of 2026, targeting various advanced solid tumors.
Iovance (NASDAQ: IOVA) CRO reports RSU vesting and tax share withholding
Iovance Biotherapeutics' Chief Regulatory Officer, Raj K. Puri, reported routine equity compensation activity involving the vesting of Restricted Stock Units (RSUs) and shares withheld for tax obligations. A total of 9,766 RSUs vested, with 3,843 shares withheld for taxes, not through an open-market sale. Following these transactions, Puri directly holds 251,957 common shares and 68,365 RSUs, with the remaining RSUs scheduled to vest quarterly.
IOVANCE (NASDAQ: IOVA) interim CEO reports RSU vesting and tax-share withholding
Frederick G. Vogt, Interim CEO and General Counsel of IOVANCE BIOTHERAPEUTICS (NASDAQ: IOVA), reported the vesting of 15,625 Restricted Stock Units (RSUs) into common stock on June 5, 2026. To cover mandatory tax withholding, 6,638 shares were withheld at $4.23 per share, which was not an open market sale. After these transactions, Vogt directly holds 562,492 shares of common stock and 109,382 RSUs, with the remaining RSUs scheduled to vest in equal quarterly installments.
IOVANCE (IOVA) Chief Medical Officer logs RSU vesting, tax-withheld shares in Form 4
Iovance Biotherapeutics' Chief Medical Officer, Friedrich Graf Finckenstein, reported routine equity compensation activity through a Form 4 filing. The report details the vesting of 7,813 restricted stock units (RSUs) and the subsequent withholding of 3,976 common shares for tax purposes. These transactions are part of a compensation plan and do not represent an open market sale.
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why
Iovance Biotherapeutics (IOVA) saw its stock jump over 30% after reporting record Q4 margins and receiving a "Buy" rating from Chardan, which trimmed its price target to $16 but still indicated a 323% upside. The company's Q4 revenue of $86.7 million beat analyst expectations, driven by strong sales of Amtagvi, and it achieved FDA Fast Track designation for Lifileucel in nonsquamous lung cancer, with significant pipeline developments expected. Operational efficiencies and the internalization of Lifileucel manufacturing are anticipated to further boost profitability and growth.
Iovance’s Amtagvi® (lifileucel) receives approval for treatment of Advanced Melanoma in Australia
Iovance Biotherapeutics' Amtagvi (lifileucel) has received conditional approval from Australia's Therapeutic Goods Administration (TGA) for advanced melanoma. This marks the third marketing authorization for Amtagvi globally. Australia has the highest melanoma rate, making this approval a significant step to address the need for new therapies for patients who have already been treated with other therapies.
Iovance rises as Australia approves melanoma therapy Amtagvi
Iovance Biotherapeutics' shares rose after Australia's Therapeutic Goods Administration (TGA) approved its melanoma therapy, Amtagvi. This approval makes Amtagvi the first and only tumor-derived T cell therapy to be approved by a regulatory body. The therapy is indicated for adult patients with unresectable or metastatic melanoma who have previously been treated with other systemic therapies.
A Look At Iovance Biotherapeutics (IOVA) Valuation After Australian Conditional Approval For Amtagvi
Iovance Biotherapeutics (IOVA) is gaining attention after Australia granted conditional approval for Amtagvi, a melanoma treatment. The stock has seen significant short-term gains, delivering a 67.86% year-to-date return, though longer-term returns remain negative. Analysts suggest the stock is 49.3% undervalued with a fair value of $8.35 per share, driven by expectations of aggressive revenue growth and future profitability.
Iovance Biotherapeutics (IOVA) Up 11% Since Q1 2026, Does it Have Further Upside Potential?
Iovance Biotherapeutics (IOVA) has seen an 11% increase in its share price since its Q1 2026 earnings report, with Wall Street analysts, including Citizens, maintaining a bullish stance and a 12-month average price target reflecting over 130% upside. The company reported $71 million in Q1 revenue, driven by its cancer therapies Amtagvi and Proleukin, and projects further revenue growth for Q2 and the full year. Iovance continues to expand its treatment network for Amtagvi, a tumor-infiltrating lymphocyte cell therapy.
Iovance rises as Australia approves melanoma therapy Amtagvi
This article reports that Iovance's stock rose following the approval of its melanoma therapy, Amtagvi, in Australia. The therapy, a tumor-infiltrating lymphocyte (TIL) treatment, is now available for adult patients with advanced unresectable or metastatic melanoma. This approval marks a significant milestone as it is the first TGA approval for a TIL therapy.
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
Iovance Biotherapeutics has received clearance for its Investigational New Drug (IND) application for IOV-5001, an IL-12 tethered TIL therapy. This next-generation therapy is designed to treat various prevalent solid tumors, including advanced colorectal and breast cancers. A Phase 1/2 basket trial is set to begin in the second half of 2026 to assess its safety and efficacy, aiming to activate "cold tumors" with enhanced safety and targeted delivery of IL-12.
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Small-Cap Stocks to Buy Now?
Iovance Biotherapeutics (IOVA) is highlighted as one of the most shorted small-cap stocks, despite a recent reiteration of a Buy rating by Chardan, though with a lowered price target due to Amtagvi's launch guidance. The company reported strong first-quarter revenue growth of 45% year-over-year to $71 million, driven by its TIL therapy Amtagvi, and projects continued revenue growth and advancing clinical trials. Iovance provides optimistic revenue guidance for Q2 ($86-$88 million) and the full year ($350-$370 million), indicating confidence in Amtagvi's commercialization.
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why
Iovance Biotherapeutics (IOVA) shares fell 8% despite the FDA refusing to approve Replimune's rival melanoma drug RP1, a development analysts expected to be positive for Iovance. Retail investors were surprised by the decline, with some speculating about FDA trial standard concerns, while analysts maintain a "Buy" rating for IOVA, citing its Amtagvi drug's competitive position and growth prospects. Overall retail sentiment for IOVA shifted to "extremely bullish" following the news.
Iovance Biotherapeutics (IOVA) Gets Australia Nod for Amtagvi, Climbs 15%
Iovance Biotherapeutics (IOVA) shares climbed 15.57% after Australia's Therapeutic Goods Administration (TGA) granted conditional approval for its melanoma therapy, Amtagvi. This marks the third market authorization for Amtagvi, following approvals in the US and Canada. The company plans to expand its presence in Australia, a country with the highest global rate of melanoma.
Iovance (NASDAQ: IOVA) CRO RSUs vest, 2,508 shares withheld for taxes
Iovance Biotherapeutics' Chief Regulatory Officer, Raj K. Puri, reported a routine equity compensation activity where 5,469 restricted stock units (RSUs) vested on June 1, 2026. Of these, 2,508 shares were withheld by the company to cover mandatory tax obligations, which was not an open-market sale. Following these transactions, Puri directly holds 242,191 common shares and 16,409 RSUs from the original grant are still pending vesting.
